loading
Schlusskurs vom Vortag:
$1.79
Offen:
$1.82
24-Stunden-Volumen:
415.40K
Relative Volume:
0.64
Marktkapitalisierung:
$48.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.24M
KGV:
-2.1721
EPS:
-0.8379
Netto-Cashflow:
$-22.47M
1W Leistung:
+26.83%
1M Leistung:
-22.88%
6M Leistung:
-63.82%
1J Leistung:
-85.84%
1-Tages-Spanne:
Value
$1.75
$1.92
1-Wochen-Bereich:
Value
$1.36
$1.92
52-Wochen-Spanne:
Value
$1.14
$13.51

Skye Bioscience Inc Stock (SKYE) Company Profile

Name
Firmenname
Skye Bioscience Inc
Name
Telefon
(858) 410-0266
Name
Adresse
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Name
Mitarbeiter
16
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
SKYE's Discussions on Twitter

Vergleichen Sie SKYE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
 icon
SKYE
Skye Bioscience Inc.
3.10 12.89M 0 0 0 0.00
 icon
MOBBW
Mobilicom Limited Warrants
0.255 398.00M 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
19.99 372.90M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.1685 343.35M 2.07B -1.42B -1.37B -0.6765
 icon
JUNE
Dhandho Junoon Etf
10.76 215.97M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
3.64 126.17M 0 0 0 0.00

Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-28 Eingeleitet William Blair Outperform
2024-09-30 Eingeleitet Scotiabank Sector Outperform
2024-09-10 Eingeleitet JMP Securities Mkt Outperform
2024-07-09 Eingeleitet Craig Hallum Buy
2024-05-23 Eingeleitet Cantor Fitzgerald Overweight
2024-04-12 Eingeleitet Oppenheimer Outperform
Alle ansehen

Skye Bioscience Inc Aktie (SKYE) Neueste Nachrichten

pulisher
Apr 23, 2025

Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com

Apr 23, 2025
pulisher
Apr 22, 2025

William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat

Apr 22, 2025
pulisher
Apr 22, 2025

(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com

Apr 22, 2025
pulisher
Apr 21, 2025

SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com

Apr 21, 2025
pulisher
Apr 19, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

William Blair Predicts Skye Bioscience Q1 Earnings - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

Brokers Offer Predictions for Skye Bioscience Q1 Earnings - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60 - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Brokers Issue Forecasts for Skye Bioscience Q2 Earnings - Defense World

Apr 18, 2025
pulisher
Apr 16, 2025

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha

Apr 16, 2025
pulisher
Apr 15, 2025

Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience reports promising obesity treatment study By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience soars after experimental weight-loss drug shows promise in mice - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss R - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model | SKYE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience reports promising obesity treatment study - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - StreetInsider

Apr 15, 2025
pulisher
Apr 15, 2025

Revolutionary Obesity Drug Combo Shows 30% Weight Loss Success in Latest Trial Data - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience to Conduct Meetings at Piper Sandler Conference - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Major Obesity Drug Developer Skye Bio Takes Center Stage at Prestigious Investor Conference - Stock Titan

Apr 14, 2025
pulisher
Apr 11, 2025

Skye Bioscience (NASDAQ:SKYE) Shares Down 50.8% – Here’s Why - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

Skye Bioscience (NASDAQ:SKYE) Trading Down 50.8% – What’s Next? - Defense World

Apr 11, 2025
pulisher
Apr 08, 2025

Skye Bioscience, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsSKYE - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025
pulisher
Mar 30, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.00 Average Price Target from Analysts - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Mar 28, 2025
pulisher
Mar 25, 2025

Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Skye Bioscience (NASDAQ:SKYE) Receives Outperform Rating from William Blair - MarketBeat

Mar 25, 2025
pulisher
Mar 25, 2025

Skye Bioscience promotes Tu Diep to COO post - The Pharma Letter

Mar 25, 2025
pulisher
Mar 25, 2025

Skye Bioscience (NASDAQ:SKYE) Price Target Cut to $14.00 by Analysts at Craig Hallum - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

Skye Bioscience (NASDAQ:SKYE) Announces Quarterly Earnings Results - MarketBeat

Mar 24, 2025
pulisher
Mar 23, 2025

Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year - Investing.com Canada

Mar 23, 2025
pulisher
Mar 23, 2025

Craig Hallum Cuts Skye Bioscience (NASDAQ:SKYE) Price Target to $14.00 - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Skye Bioscience’s (SKYE) “Outperform” Rating Reiterated at William Blair - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Craig Hallum Issues Pessimistic Forecast for Skye Bioscience (NASDAQ:SKYE) Stock Price - Defense World

Mar 23, 2025

Finanzdaten der Skye Bioscience Inc-Aktie (SKYE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Skye Bioscience Inc-Aktie (SKYE) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Diep Tuan Tu
Chief Development Officer
Nov 15 '24
Sale
5.55
85
472
101,748
ARSENAULT KAITLYN
Chief Financial Officer
Nov 18 '24
Sale
4.99
43,206
215,598
166,342
ARSENAULT KAITLYN
Chief Financial Officer
Nov 15 '24
Sale
5.55
190
1,054
209,548
DHILLON PUNIT
Chief Executive Officer
Nov 18 '24
Sale
4.99
82,546
411,905
329,823
DHILLON PUNIT
Chief Executive Officer
Nov 15 '24
Sale
5.55
364
2,020
412,369
Grayson Paul A.
Director
Nov 18 '24
Sale
4.99
86,244
430,358
259,701
Grayson Paul A.
Director
Nov 15 '24
Sale
5.55
307
1,704
345,945
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Kapitalisierung:     |  Volumen (24h):